Boston Common Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.5M | Sell |
46,063
-4,900
| -10% | -$2.18M | 0.57% | 59 |
|
|
2025
Q1 | $24.7M | Buy |
50,963
+671
| +1% | +$325K | 0.75% | 41 |
|
|
2024
Q4 | $20.3M | Buy |
50,292
+26
| +0.1% | +$10.5K | 0.59% | 59 |
|
|
2024
Q3 | $23.4M | Buy |
50,266
+13,008
| +35% | +$6.05M | 0.61% | 53 |
|
|
2024
Q2 | $17.5M | Sell |
37,258
-2,061
| -5% | -$966K | 0.45% | 86 |
|
|
2024
Q1 | $16.4M | Sell |
39,319
-16,038
| -29% | -$6.7M | 0.39% | 97 |
|
|
2023
Q4 | $22.5M | Sell |
55,357
-2,670
| -5% | -$1.09M | 0.51% | 74 |
|
|
2023
Q3 | $20.2M | Sell |
58,027
-1,210
| -2% | -$421K | 0.48% | 78 |
|
|
2023
Q2 | $20.8M | Sell |
59,237
-15,499
| -21% | -$5.45M | 0.45% | 83 |
|
|
2023
Q1 | $23.5M | Sell |
74,736
-2,568
| -3% | -$809K | 0.49% | 72 |
|
|
2022
Q4 | $22.3M | Buy |
77,304
+2,027
| +3% | +$585K | 1.07% | 27 |
|
|
2022
Q3 | $21.8M | Buy |
75,277
+20,308
| +37% | +$5.88M | 1.14% | 27 |
|
|
2022
Q2 | $15.5M | Buy |
54,969
+23,085
| +72% | +$6.51M | 0.77% | 44 |
|
|
2022
Q1 | $8.32M | Buy |
31,884
+844
| +3% | +$220K | 0.36% | 89 |
|
|
2021
Q4 | $6.82M | Sell |
31,040
-505
| -2% | -$111K | 0.28% | 99 |
|
|
2021
Q3 | $5.72M | Sell |
31,545
-169
| -0.5% | -$30.7K | 0.25% | 100 |
|
|
2021
Q2 | $6.39M | Buy |
31,714
+7,635
| +32% | +$1.54M | 0.27% | 94 |
|
|
2021
Q1 | $5.17M | Buy |
+24,079
| New | +$5.17M | 0.33% | 89 |
|